Breast cancer cell lines sensitive to the MEK inhibitor selumetinib tend to be a basal subtype with Raf mutations [102], and a number of MEK inhibitors are in early clinical trials across solid tumour types, although information on breast cancer responsiveness is still scarce [103]. The gene discussed is MAP2K7; the disease is breast carcinoma.